Fortress Biotech, Inc.
CIK 1429260 · Lihat di SEC EDGAR ↗
Pengajuan SEC Pertama: 6 Jan. 2026 · Terbaru: 6 Jan. 2026
Di halaman ini
- Biografi Latar belakang karier dan profil publik, jika tersedia.
- Orang Dalam di Perusahaan di mana orang ini adalah orang dalam yang melaporkan.
- Transaksi orang dalam Setiap saham yang dibeli atau dijual orang ini, dari pengajuan Formulir 4.
- Derivatif Opsi dan kepemilikan derivatif lainnya yang dilaporkan oleh orang ini.
- Kepemilikan Awal Kepemilikan yang dimiliki orang ini saat pertama kali mulai melaporkan.
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
Baca selengkapnya
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
History
The company was founded in 2006 under the name Coronado Biosciences, initially as an oncology company. In 2011, it was announced that Coronado raised $47.4 million in funding. Shortly thereafter it became a public company by registering all of its private shares as common stock. The company changed its name to Fortress Biotech in April 2015.
In November 2019, Fortress Biotech was ranked number 10 in the 2019 Deloitte Technology Fast 500 annual rankings.
Subsidiaries
Fortress Bio has 10 biopharmaceutical subsidiary companies which cover a range of medical therapy areas, including potential cancer treatments and therapies for rare diseases and conditions. These subsidiaries include Aevitas Therapeutics (formed in 2017), Avenue Therapeutics (formed in 2015), Caelum Biosciences (formed in 2017), Cellvation (formed in 2016), Checkpoint Therapeutics (formed in 2015), Cyprium Therapeutics (formed in 2017), Helocyte (formed in 2015), Journey Medical Corporation (formed in 2014), Mustang Bio (formed in 2015), Tamid Bio (formed in 2017) and Baergic Bio (formed in 2019).
Products
Fortress Bio’s marketed products are developed and commercialized by its subsidiary Journey Medical Corporation. These include Targadox tablets indicated for acne, eczema emollient Ceracade, wound cream Luxamend, topical corticosteroid Triderm, topical broad-spectrum antifungal solution Exelderm, Ala-Quin topical cream for skin conditions, and Ala-Scalp hydrocortisone lotion for skin conditions.
== References ==
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
Orang Dalam di
Transaksi orang dalam
Perubahan harga vs kuotasi saat ini, disesuaikan split untuk aksi korporasi sejak pengajuan — tidak dibenchmark, tidak diannualisasi, tidak dibobot berdasarkan ukuran
| Tanggal | Ticker | Kode | Saham | Harga | Nilai | Dimiliki setelah | Δ milik | A/D | vs sekarang |
|---|---|---|---|---|---|---|---|---|---|
| 29 Mei 2025 | FBIOP | S | 100.000 | $1,29 | $129.000 | 6.122.249 Langsung | -1,61% | Dilepas | 1322,5% (harga per 2026-08-21) |
P = Pembelian pasar terbuka · S = Penjualan · A = Hibah/penghargaan · B = Pelaksanaan opsi · G = Hadiah · F = Pemotongan pajak
Transaksi orang dalam bukan merupakan rekomendasi; penjualan sering kali didorong oleh alasan likuiditas atau pajak.
Kepemilikan Derivatif (Formulir 4 Tabel II)
Opsi, RSU, dan sekuritas konversi yang dilaporkan pada Formulir 4 Tabel II.
| Tanggal | Ticker | Sekuritas | Underlying | Harga Pelaksanaan | Kedaluwarsa | Saham | A/D |
|---|---|---|---|---|---|---|---|
| 30 Mei 2025 | FBIOP | CLASS A COMMON STOCK, PAR VALUE $0.0001 | Common Stock (700.000) | $4,10 | — | 700.000 | Dilepas |
Harga pelaksanaan/konversi kosong jika tidak berlaku (misalnya, RSU).
Kepemilikan Awal (Formulir 3) 12 saham
Sekuritas yang dipegang saat pertama kali menjadi orang dalam, sesuai Formulir 3 SEC.
| Tanggal | Ticker | Sekuritas | Saham | Kepemilikan |
|---|---|---|---|---|
| 3 Jan. 2025 | FBIOP | COMMON STOCK, PAR VALUE $0.0001 | 6.552.784 | Langsung |
| 3 Jan. 2025 | FBIOP | COMMON STOCK, PAR VALUE $0.0001 | 294.800 | Langsung |
| 31 Mei 2024 | DERM | COMMON STOCK, PAR VALUE $0.0001 | 4.110.467 | Langsung |
| 31 Mei 2024 | DERM | Common stock - Class A, $0.0001 par value→ Common Stock (6.000.000) | 6.000.000 | Langsung |
| 24 Mei 2024 | FBIOP | COMMON STOCK, PAR VALUE $0.0001 | 3.589.193 | Langsung |
| 24 Mei 2024 | FBIOP | CLASS A COMMON STOCK, PAR VALUE $0.0001→ Common Stock (700.000) | 700.000 | Langsung |
| 23 Agu 2017 | FBIOP | Common Stock | 3.316.259 | Langsung |
| 23 Agu 2017 | FBIOP | Class A Preferred Stock | 250.000 | Langsung |
| 7 Juni 2017 | FBIOP | Common Stock, $0.0001 par value | 1.981.006 | Langsung |
| 7 Juni 2017 | FBIOP | Class A Common Stock, $0.001 par value→ Common Stock (7.000.000) | 7.000.000 | Langsung |
| 7 Juni 2017 | FBIOP | Common Stock, par value $0.0001 | 9.000.000 | Langsung |
| 7 Juni 2017 | FBIOP | Class A Preferred Stock, $0.0001 par value→ Common Stock (250.000) | 250.000 | Langsung |